FL058

DRUG2 trials

Sponsors

Qilu Pharmaceutical Co., Ltd.

Conditions

Healthy

Phase 1

Evaluation of the Safety, Tolerability and Pharmacokinetics of Intravenous FL058 Administered in Healthy Subjects(SAD/MAD)

CompletedNCT05055687

Qilu Pharmaceutical Co., Ltd.Healthy

Start: 2020-07-05End: 2020-07-27Updated: 2021-09-24

Evaluation of the Safety, Tolerability and Pharmacokinetics of Intravenous FL058 Administered in Healthy Subjects(SAD)

CompletedNCT05058118

Qilu Pharmaceutical Co., Ltd.Healthy

Start: 2019-12-08End: 2020-06-03Updated: 2021-09-27

Related Papers

First-in-human study to evaluate the safety, tolerability, and population pharmacokinetic/pharmacodynamic target attainment analysis of FL058 alone and in combination with meropenem in healthy subjects

Antimicrobial Agents and Chemotherapy2023-12-067 citations